Studies (7) have shown that patients with high-density tumor antigen-specific CD8+ T lymphocytes at the invasive tumor edge are more likely to benefit from treatment with programmed death 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) inhibitors. The gene discussed is CD8A; the disease is neoplasm.